135 related articles for article (PubMed ID: 29735397)
1. Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy.
Flannery K; Cao X; He J; Zhong Y; Shah AY; Kamat AM
Clin Genitourin Cancer; 2018 Aug; 16(4):e909-e917. PubMed ID: 29735397
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
3. Provider treatment intensity and outcomes for patients with early-stage bladder cancer.
Hollenbeck BK; Ye Z; Dunn RL; Montie JE; Birkmeyer JD
J Natl Cancer Inst; 2009 Apr; 101(8):571-80. PubMed ID: 19351919
[TBL] [Abstract][Full Text] [Related]
4. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.
Rose TL; Deal AM; Nielsen ME; Smith AB; Milowsky MI
Cancer; 2016 Jul; 122(13):2012-20. PubMed ID: 27224661
[TBL] [Abstract][Full Text] [Related]
5. The Cost to Medicare of Bladder Cancer Care.
Sloan FA; Yashkin AP; Akushevich I; Inman BA
Eur Urol Oncol; 2020 Aug; 3(4):515-522. PubMed ID: 31412015
[TBL] [Abstract][Full Text] [Related]
6. Impact of malpractice caps on use and outcomes of radical cystectomy for bladder cancer: data from the surveillance, epidemiology, and end results program.
Konety BR; Dhawan V; Allareddy V; Joslyn SA
J Urol; 2005 Jun; 173(6):2085-9. PubMed ID: 15879848
[TBL] [Abstract][Full Text] [Related]
7. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
Ramsey SD; Howlader N; Etzioni RD; Donato B
J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study.
Shao C; He J; Stein K; Keefe S
Curr Med Res Opin; 2020 Jul; 36(7):1187-1194. PubMed ID: 32314603
[No Abstract] [Full Text] [Related]
10. Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.
Bao Y; Maciejewski RC; Garrido MM; Shah MA; Maciejewski PK; Prigerson HG
J Pain Symptom Manage; 2018 Apr; 55(4):1113-1121.e3. PubMed ID: 29241809
[TBL] [Abstract][Full Text] [Related]
11. Clinical model of cost of bladder cancer in the elderly.
Cooksley CD; Avritscher EB; Grossman HB; Sabichi AL; Dinney CP; Pettaway C; Elting LS
Urology; 2008 Mar; 71(3):519-25. PubMed ID: 18342201
[TBL] [Abstract][Full Text] [Related]
12. A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends.
Koay EJ; Teh BS; Paulino AC; Butler EB
Cancer; 2011 Dec; 117(23):5325-33. PubMed ID: 21567387
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
14. Understanding the variation in treatment intensity among patients with early stage bladder cancer.
Hollingsworth JM; Zhang Y; Krein SL; Ye Z; Hollenbeck BK
Cancer; 2010 Aug; 116(15):3587-94. PubMed ID: 20564128
[TBL] [Abstract][Full Text] [Related]
15. Medical care costs and survival associated with hepatocellular carcinoma among the elderly.
White LA; Menzin J; Korn JR; Friedman M; Lang K; Ray S
Clin Gastroenterol Hepatol; 2012 May; 10(5):547-54. PubMed ID: 22210536
[TBL] [Abstract][Full Text] [Related]
16. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA.
Steuten L; Garmo V; Phatak H; Sullivan SD; Nghiem P; Ramsey SD
Appl Health Econ Health Policy; 2019 Oct; 17(5):733-740. PubMed ID: 31250217
[TBL] [Abstract][Full Text] [Related]
18. The economics of bladder cancer: costs and considerations of caring for this disease.
Svatek RS; Hollenbeck BK; Holmäng S; Lee R; Kim SP; Stenzl A; Lotan Y
Eur Urol; 2014 Aug; 66(2):253-62. PubMed ID: 24472711
[TBL] [Abstract][Full Text] [Related]
19. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.
Choong NW; Quevedo JF; Kaur JS
Cancer; 2005 Mar; 103(6):1172-8. PubMed ID: 15700264
[TBL] [Abstract][Full Text] [Related]
20. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
